Table 2.
Descriptive statistics of change in mGFR, eGFR (Cockcroft-Gault) and serum creatinine (full analysis set)
| mGFR (mL/min/1.73 m 2 ) | eGFR (Cockcroft-Gault) (mL/min/1.73 m 2 ) | Serum creatinine (mg/dL) | ||||
|---|---|---|---|---|---|---|
| Tofacitinib → placebo group | Placebo → placebo group | Tofacitinib → placebo group | Placebo → placebo group | Tofacitinib → placebo group | Placebo → placebo group | |
| Baseline | ||||||
| Number | 97 | 51 | 97 | 51 | 97 | 51 |
| Mean (SD) | 88.98 (18.79) | 89.67 (21.33) | 104.19 (28.42) | 111.30 (26.91) | 0.77 (0.15) | 0.76 (0.17) |
| Median (Q1, Q3) | 87.98 (75.76, 99.98) | 86.99 (75.17, 98.20) | 97.22 (82.43, 125.57) | 107.22 (91.47, 134.89) | 0.76 (0.67, 0.85) | 0.75 (0.64, 0.84) |
| Change at end of period 1 from baseline | ||||||
| Number | 91 | 46 | 92 | 46 | 92 | 46 |
| Mean (SD) | −6.73 (16.44) | −0.50 (17.34) | −3.59 (10.31) | 1.28 (11.48) | 0.03 (0.07) | −0.00 (0.07) |
| Median (Q1, Q3) | −6.46 (−11.85, 2.14) | 0.82 (−5.48, 6.79) | −3.36 (−9.18, 2.86) | 2.30 (−5.71, 6.14) | 0.02 (−0.02, 0.08) | −0.01 (−0.05, 0.04) |
| Change at end of period 2 from baseline | ||||||
| Number | 86 | 45 | 87 | 44 | 87 | 44 |
| Mean (SD) | −3.02 (17.55) | −5.96 (20.66) | 0.03 (10.15) | 0.48 (9.54) | 0.00 (0.07) | −0.00 (0.05) |
| Median (Q1, Q3) | −3.41 (−8.55, 3.65) | −3.88 (−9.13, 7.58) | −0.32 (−6.05, 5.74) | 0.18 (−3.81, 4.28) | 0.00 (−0.05, 0.05) | 0.00 (−0.03, 0.03) |
| Change at end of period 2 from end of period 1 | ||||||
| Number | 86 | 45 | 87 | 44 | 87 | 44 |
| Mean (SD) | 2.92 (19.02) | −5.41 (16.65) | 3.71 (11.95) | −0.97 (10.06) | −0.03 (0.08) | 0.00 (0.07) |
| Median (Q1, Q3) | 1.68 (−3.60, 8.62) | −3.25 (−12.24, 2.29) | 2.94 (−4.45, 10.31) | −2.07 (−7.29, 6.09) | −0.02 (−0.07, 0.03) | 0.01 (−0.04, 0.05) |
eGFR, estimated glomerular filtration rate; mGFR, measured glomerular filtration rate; Q1, 25th percentile; Q3, 75th percentile; SD, standard deviation.